The Neurobiology of Depressive Illness
Study Details
Study Description
Brief Summary
We aim to determine why patients with depression are at an elevated risk for the development of coronary heart disease, and resolve whether the severity of a patient's depression has a counterpart in demonstrable abnormalities in brain chemistry. Studies will be completed in 28 patients with depression; both males and females. Patients will be studied both untreated and during administration of a selective serotonin re-uptake inhibitor (SSRI) antidepressant. They will be either newly diagnosed with depression, untreated patients suffering a recent relapse, or patients seeking to switch from a non-SSRI antidepressant due to non-response. The turnover of chemical messengers in the brain will be estimated by high internal jugular venous blood sampling and DNA will be isolated and examined from blood cells. Immune function will also be assessed. Whole body and cardiac sympathetic nervous activity will be determined, as well as microneurographic recording of muscle sympathetic nervous activity.
It is hypothesised that patients with depression and no existing demonstrable cardiac disease demonstrate:
Alterations in brain monoaminergic neurotransmitter turnover, resulting in sympathetic nervous activation and dysregulation of the baroreflex control to both the heart (vagal) and muscle vasoconstrictor sympathetic nerves; and Exhibit enhanced platelet reactivity predisposing them to thrombogenesis and myocardial ischaemia.
Therapeutic intervention with an SSRI will modify cardiac sympathetic function, baroreflex sensitivity or platelet reactivity in a fashion likely to reduce cardiac risk.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: intervention there is no sham or placebo control arm It is a single arm study |
Drug: antidepressants primarily selective serotonin reuptake inhibitors
normal clinical dosages used according to clinical response as determined by a psychiatrist
|
Outcome Measures
Primary Outcome Measures
- level of sympathetic nervous system activity and its response to treatment [12 weeks]
Secondary Outcome Measures
- clinical response to treatment [12 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
- Major depression
Exclusion Criteria:
- heart disease diabetes hypertension psychosis significant suicidal risk dementia
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Baker Heart Research Institute | Melbourne | Victoria | Australia | 3 |
Sponsors and Collaborators
- Baker Heart Research Institute
- National Health and Medical Research Council, Australia
Investigators
- Principal Investigator: Murray A Esler, MBBS Phd, Baker Heart Research Insitute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NHMRC D-01